News
GTBP
3.720
-3.13%
-0.120
GT Biopharma, Inc. Stockholders Approve Increase in Authorized Shares to 250,000,000 and Share Issuance Proposal
NASDAQ · 1d ago
GT Biopharma Stockholders Approve Key Charter and Share Proposals
TipRanks · 2d ago
GT Biopharma Explores A New Combination Approach For Pancreatic Cancer
Simply Wall St · 4d ago
Weekly Report: what happened at GTBP last week (1102-1106)?
Weekly Report · 5d ago
Weekly Report: what happened at GTBP last week (1026-1030)?
Weekly Report · 11/02 09:09
Weekly Report: what happened at GTBP last week (1019-1023)?
Weekly Report · 10/26 09:09
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 10/21 17:05
Weekly Report: what happened at GTBP last week (1012-1016)?
Weekly Report · 10/19 09:09
Weekly Report: what happened at GTBP last week (1005-1009)?
Weekly Report · 10/12 09:10
GT Biopharma registers to sell 13.5M shares of common stock for holders
TipRanks · 10/09 21:35
GT Biopharma Files Prospectus Related To The Offer Up To 13,502,835 Shares Of Common Stock By Selling Stockholders
Benzinga · 10/09 21:32
Weekly Report: what happened at GTBP last week (0928-1002)?
Weekly Report · 10/05 09:10
Weekly Report: what happened at GTBP last week (0921-0925)?
Weekly Report · 09/28 09:09
GT Biopharma Regains Nasdaq Minimum Bid Compliance
TipRanks · 09/25 20:54
GT Biopharma Expands Series M Preferred Financing Agreement
TipRanks · 09/21 20:56
Weekly Report: what happened at GTBP last week (0914-0918)?
Weekly Report · 09/21 09:09
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 09/15 17:06
GT Biopharma's GTB-5550 Secures FDA IND Clearance For Multiple Myeloma; Stock Down
NASDAQ · 09/15 14:52
GT Biopharma trading resumes
TipRanks · 09/15 13:45
GT Biopharma trading halted, volatility trading pause
TipRanks · 09/15 13:35
More
Webull provides a variety of real-time GTBP stock news. You can receive the latest news about Gt Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About GTBP
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.